Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$37.91 USD
+0.10 (0.26%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $37.93 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.91 USD
+0.10 (0.26%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $37.93 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Roche (RHHBY) Stops Dosing in Huntington's Disease Study
by Zacks Equity Research
Roche (RHHBY) halts dosing in the phase III GENERATION HD1 study evaluating tominersen in manifest Huntington's disease following recommendation from an iDMC.
Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails
by Zacks Equity Research
Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.
Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates
by Zacks Equity Research
Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -1116.67% and 9.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for February 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Why Is Ionis Pharmaceuticals (IONS) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) Misses Estimates for Q3 Earnings and Sales
by Zacks Equity Research
Ionis (IONS) posts wider-than-expected Q3 loss. Sales miss estimates.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -144.44% and -15.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' Alexander Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation to Ionis' (IONS) pipeline candidate ION373 for treating patients with Alexander disease.
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis
by Zacks Equity Research
Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.
Why Is Ionis Pharmaceuticals (IONS) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis to Acquire Remaining Stake in Akcea, Stocks Rally
by Zacks Equity Research
Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.
Ionis (IONS) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Ionis (IONS) posts narrower-than-expected Q2 loss. Sales miss estimates.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 17.86% and -3.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akcea (AKCA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Akcea (AKCA) reports Q2 results.
Biogen to Pit Spinraza Against Novartis' Zolgensma in Phase IV
by Zacks Equity Research
Biogen (BIIB) intends to start a phase IV study for the assessment of Spinraza's safety in infants and children with SMA who showed a suboptimal clinical response to Novartis' Zolgensma.
USANA (USNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
USANA (USNA) will release second-quarter 2020 results, which are likely to reflect impacts of the COVID-19 pandemic.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
by Zacks Equity Research
Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group
Grab 5 Top Stocks With Strong Earnings Beat Prospects
by Sanghamitra Saha
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
Why Ionis Pharmaceuticals (IONS) Stock Might be a Great Pick
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well